CSL Résultats passés
Passé contrôle des critères 1/6
CSL a connu une croissance annuelle moyenne de ses bénéfices de 0.3%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 17.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 10.6% par an. Le rendement des capitaux propres de CSL est 6.7% et ses marges nettes sont de 9.1%.
Informations clés
0.26%
Taux de croissance des bénéfices
-1.27%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 9.61% |
| Taux de croissance des recettes | 10.56% |
| Rendement des fonds propres | 6.68% |
| Marge nette | 9.06% |
| Prochaine mise à jour des résultats | 18 Aug 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jul 09
CSL: Roofing Platform Repricing Will Drive Future Rebound Case
Analysts have reduced their price target on CSL to about A$196.66 from about A$289.37, citing updated assumptions around discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent research around CSL highlights a split in views, with some cautious adjustments to assumptions and at least one downgrade, while other coverage of the broader roofing sector points to potential catalysts that investors may still weigh when assessing CSL.
Nouveau récit • Jun 28
Strong buy. World-leading healthcare company with steady growth
CSL is one of Australia’s highest-quality businesses and has a long history of delivering strong returns. It is a global leader in plasma therapies, vaccines and biotechnology, with products that are difficult to replicate and protected by strict regulation.
Mise à jour du récit • Jun 25
CSL: Cost Cuts And Capacity Expansion Will Support Long Term Earnings Recovery
Analysts have trimmed their price target on CSL to about A$138 from roughly A$141. This reflects a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a lower future P/E multiple in their updated valuation work.Article d’analyse • Jun 16
CSL (ASX:CSL) Shares Could Be 31.5% Undervalued Before Full Year Results
CSL (ASX:CSL) is back in focus after a sharp share price rebound, with investors weighing the upcoming August 18 full-year results and dividend announcement against recent guidance cuts and asset impairments. See our latest analysis for CSL. The recent rebound has lifted CSL’s 7 day share price return to 6.8% and its 30 day share price return to 8.5%. However, its year to date share price return is still down 38.2% and the 1 year total shareholder return has declined 54.5%. This indicates...Mise à jour du récit • Jun 11
CSL: Cost Transformation And Capacity Expansion Will Support Long Term Earnings Power
Narrative Update on CSL The analyst fair value estimate for CSL has been revised from A$146.21 to A$140.86, with analysts citing updated assumptions for revenue growth, profit margins and forward P/E multiples in light of recent sector and company specific research. Analyst Commentary Recent research on CSL has pointed to a mix of optimism and caution, with valuation assumptions and execution risks front and center.
Nouveau récit • Jun 10
CSL Investment Thesis
CSL Limited Australian Securities Exchange · ASX: CSL · Plasma therapeutics, vaccines, nephrology RECOMMENDATION: DEFER INITIATION — do not deploy capital before the 18 August 2026 FY26 result. The thesis hinges on a single variable — whether the core Behring franchise is derating permanently or cyclically — which resolves on a known date roughly ten weeks out.Mise à jour du récit • May 27
CSL: U.S. Capacity Expansion Will Support Long Term Earnings Power
Analysts have revised CSL's fair value estimate down from A$195.41 to A$146.21. This reflects updated views on slightly higher discount rates, more moderate revenue growth, softer profit margins and a lower assumed future P/E multiple.Mise à jour du récit • May 09
CSL: U.S. Manufacturing Expansion And CEO Transition Will Support Long Term Upside
CSL's analyst price target has been adjusted slightly lower to A$195.41 from A$198.79 as analysts factor in marginally softer revenue growth, a small reduction in projected profit margins, a slightly lower discount rate, and a modestly lower future P/E assumption. Analyst Commentary Recent Street research on the sector, including coverage of CSL peers, points to a mix of optimism about execution and long term growth, alongside pockets of caution on valuation and macro sensitivity.Mise à jour du récit • Apr 22
CSL: Manufacturing Expansion And CEO Transition Will Support Long Term Share Rebound
The CSL analyst price target has been trimmed by about A$9, as analysts now factor in slightly lower revenue growth, a modestly softer profit margin outlook, a marginally higher discount rate and a small reset in assumed future P/E multiples. Analyst Commentary Recent Street research on CSL and peers points to a mixed but useful read on how analysts are thinking about valuation, execution risk and growth expectations.Mise à jour du récit • Apr 08
CSL: Manufacturing Expansion And CEO Transition Will Support Future Share Recovery
Analysts have slightly increased CSL's fair value estimate to A$208.11, citing modest adjustments to the discount rate, revenue growth, profit margin and a higher assumed future P/E multiple as they reassess the stock following recent rating changes. Analyst Commentary Recent rating actions around CSL highlight a split in views on how much investors should pay for the stock at this stage, which feeds directly into the updated fair value estimate of A$208.11.Mise à jour du récit • Mar 25
CSL: Manufacturing Expansion And Horizon 2 Rollout Will Support Future Share Recovery
Narrative Update on CSL Analysts have adjusted CSL's fair value estimate from A$205.16 to A$207.81. This reflects updated views on its discount rate, revenue growth, profit margins and future P/E assumptions, alongside recent mixed rating actions on the stock.Mise à jour du récit • Mar 10
CSL: Manufacturing Expansion And Leadership Transition Will Support Future Share Recovery
Analysts have trimmed their CSL price target by about A$6 to reflect slightly lower long term fair value estimates, modestly higher discount rates and more conservative assumptions for revenue growth and profit margins, partially offset by a higher future P/E multiple. Analyst Commentary Recent Street research around CSL points to a mixed setup, with some firms taking a more constructive stance and others turning cautious.Nouveau récit • Mar 09
CSL: The Dip Is the Opportunity
CSL: The Dip Is the Opportunity Most people look at CSL's stock chart right now and see a problem. Down 35% from its highs, margins cut in half, and a company in the middle of its biggest restructuring in decades.Mise à jour du récit • Feb 24
CSL: Execution On Gene Therapy And Leadership Transition Will Support Share Recovery
Analysts have trimmed their CSL fair value estimate to A$210.90 from A$228.58 as updated assumptions on discount rate, revenue growth, profit margins and future P/E feed through into a lower overall price target. Analyst Commentary Recent research views on CSL have been mixed, with some analysts turning more cautious while others have taken a more constructive stance at different points.Nouveau récit • Feb 22
My view on CSL Limited is positive. It’s a high-quality growth stock with strong barriers to entry through its global plasma network.
One stock I find particularly compelling is CSL Limited (ASX: CSL), primarily due to its strong competitive positioning, structural growth drivers, and valuation complexity. From a fundamental perspective, CSL operates in the global plasma therapies and specialty pharmaceuticals market, where demand is relatively inelastic and supported by long-term healthcare trends.Article d’analyse • Feb 17
CSL's (ASX:CSL) Soft Earnings Are Actually Better Than They Appear
Investors were disappointed with the weak earnings posted by CSL Limited ( ASX:CSL ). While the headline numbers were...Mise à jour du récit • Feb 10
CSL: Share Recovery Will Be Supported By Execution And Recent Upgrade
Analysts have trimmed their fair value estimate for CSL to about A$228.58 from A$232.54, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research on CSL points to a mix of optimism and caution, which helps explain the modest trim in fair value.
Nouveau récit • Feb 07
Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook
Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Jan 26
CSL: Share Recovery Will Be Driven By Seqirus Reset And Demerger Deferral
Analysts have raised their fair value target for CSL to A$232.54. This reflects slightly adjusted assumptions for revenue growth, profit margins and future P/E multiples after recent upgrades and renewed interest in the shares.Mise à jour du récit • Jan 11
CSL: Shares Will Recover As Seqirus Reset And Demerger Deferral Settle
Analysts have trimmed their CSL price target slightly, with fair value moving from about A$236.57 to A$232.45, as they factor in softer Seqirus vaccination trends and the deferred vaccine demerger, while still seeing the recent share pullback as an opportunity to re-engage with the stock. Analyst Commentary Recent research on CSL focuses heavily on the updated outlook for Seqirus, the indefinitely deferred vaccine demerger, and where the current share price sits relative to revised fair value estimates.Mise à jour du récit • Dec 17
CSL: Shares Will Recover As Seqirus Drag Fades After AGM Downgrade
Analysts have nudged down their price target on CSL by A$5 to reflect slightly softer long term revenue growth assumptions and a modestly higher discount rate, even as they highlight resilient margins and view the recent selloff as an opportunity to re engage with the shares. Analyst Commentary Recent commentary around CSL reflects a more constructive stance on the stock despite near term earnings noise, with valuation support emerging after the sharp pullback.Mise à jour du récit • Dec 03
CSL: Shares Will Recover As Seqirus Headwinds Ease After Recent Pullback
Analysts have trimmed their price target on CSL slightly, from about A$230 to A$225, reflecting tempered expectations for Seqirus amid weaker U.S. vaccination trends and the indefinite deferral of the planned vaccine business demerger, even as they note that the recent share price correction has opened a more attractive entry point. Analyst Commentary Analyst views on CSL have turned more constructive following the share price pullback, even as earnings expectations have been nudged lower to reflect the softer outlook for Seqirus.Mise à jour du récit • Nov 19
CSL: Share Price Will Rebound After Vaccine Demerger Deferral And Segment Headwinds
Analysts have marginally increased their fair value estimate for CSL from $246.49 to $246.96. This reflects a cautiously optimistic outlook as concerns over segment performance and revised vaccination forecasts are balanced by expectations of a market overreaction and longer-term recovery potential.Mise à jour du récit • Nov 04
CSL: Share Price Correction Will Present Opportunity As Vaccine Uncertainty Eases
CSL's analyst price target has been lowered from A$280.61 to A$246.49, reflecting analysts' revised expectations following recent updates about weaker revenue growth, a more cautious profit margin outlook, and continued challenges in key business units. Analyst Commentary Market analysts have offered mixed perspectives on CSL following recent trading updates and management commentary, resulting in shifts in both ratings and price targets.Mise à jour du récit • Oct 21
Analysts Adjust CSL Outlook as Valuation Rises Amid Mixed Market Sentiment and Company Updates
CSL's fair value estimate has increased modestly by $0.23 to $280.61, as analysts factor in softened revenue and profit margin assumptions in light of near-term challenges in end-market demand and distributor activity. Analyst Commentary Recent street research reflects both cautious and optimistic views toward CSL's near-term execution and longer-term prospects.Mise à jour du récit • Oct 03
Operational Improvements Will Unlock Biotech Potential And China Market Expansion
The analyst consensus price target for CSL has been revised downward by 1.5% to $280.38. Analysts cite near-term uncertainties in end-market demand and distribution dynamics as key factors in the updated valuation.Article d’analyse • Sep 25
CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 21x in Australia, you could be forgiven for feeling...Mise à jour du récit • Sep 04
Operational Improvements Will Unlock Biotech Potential And China Market Expansion
Despite the consensus Analyst Price Target for CSL remaining largely unchanged, the significant increase in Future P/E from 26.27x to 40.16x indicates investor expectations for higher earnings growth or a premium valuation, resulting in only a marginal fair value decrease to A$284.79. What's in the News CSL plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by end of FY26, along with job cuts and a share repurchase program to allow strategic autonomy.Mise à jour du récit • Aug 20
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
CSL's consensus price target has been revised downward, reflecting a material drop in expected revenue growth alongside a sharply higher future P/E ratio, with fair value now set at A$291.99. What's in the News CSL expects group revenue growth of approximately 4-5% and NPATA growth of 7-10% for FY26, excluding non-recurring restructuring costs.Article d’analyse • Aug 07
Is CSL Limited (ASX:CSL) Trading At A 43% Discount?
ASX:CSL 1 Year Share Price vs Fair Value Explore CSL's Fair Values from the Community and select yours Key Insights The...Nouveau récit • Apr 15
CSL is undervalued in High Tax Scenario
CSL Behring: This is CSL's largest segment and the global leader (#1) in plasma therapies within an estimated US$30 billion industry.11 It focuses on researching, developing, manufacturing, and distri
Nouveau récit • Feb 23
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings.Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment CSL gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 25 | 15,407 | 1,396 | 2,661 | 1,313 |
| 30 Sep 25 | 15,483 | 2,199 | 2,639 | 1,336 |
| 30 Jun 25 | 15,558 | 3,002 | 2,616 | 1,359 |
| 31 Mar 25 | 15,394 | 2,875 | 2,574 | 1,382 |
| 31 Dec 24 | 15,230 | 2,748 | 2,531 | 1,405 |
| 30 Sep 24 | 15,015 | 2,695 | 2,456 | 1,417 |
| 30 Jun 24 | 14,800 | 2,642 | 2,381 | 1,428 |
| 31 Mar 24 | 14,490 | 2,557 | 2,296 | 1,385 |
| 31 Dec 23 | 14,179 | 2,472 | 2,211 | 1,342 |
| 30 Sep 23 | 13,745 | 2,333 | 2,260 | 1,304 |
| 30 Jun 23 | 13,310 | 2,194 | 2,308 | 1,266 |
| 31 Mar 23 | 12,507 | 2,156 | 2,168 | 1,265 |
| 31 Dec 22 | 11,705 | 2,118 | 2,028 | 1,263 |
| 30 Sep 22 | 11,133 | 2,186 | 1,839 | 1,210 |
| 30 Jun 22 | 10,562 | 2,255 | 1,649 | 1,156 |
| 31 Mar 22 | 10,587 | 2,290 | 1,711 | 1,108 |
| 31 Dec 21 | 10,612 | 2,325 | 1,773 | 1,060 |
| 30 Sep 21 | 10,461 | 2,350 | 1,742 | 1,031 |
| 30 Jun 21 | 10,310 | 2,375 | 1,712 | 1,001 |
| 31 Mar 21 | 10,145 | 2,520 | 1,612 | 953 |
| 31 Dec 20 | 9,980 | 2,665 | 1,511 | 904 |
| 30 Sep 20 | 9,565 | 2,384 | 1,550 | 913 |
| 30 Jun 20 | 9,151 | 2,103 | 1,588 | 922 |
| 31 Mar 20 | 9,048 | 2,054 | 1,557 | 904 |
| 31 Dec 19 | 8,944 | 2,006 | 1,527 | 886 |
| 30 Sep 19 | 8,742 | 1,962 | 1,484 | 859 |
| 30 Jun 19 | 8,539 | 1,919 | 1,442 | 832 |
| 31 Mar 19 | 8,406 | 1,861 | 1,441 | 791 |
| 31 Dec 18 | 8,274 | 1,803 | 1,441 | 751 |
| 30 Sep 18 | 8,094 | 1,766 | 1,371 | 726 |
| 30 Jun 18 | 7,915 | 1,729 | 1,301 | 702 |
| 31 Mar 18 | 7,666 | 1,674 | 1,251 | 713 |
| 31 Dec 17 | 7,417 | 1,618 | 1,200 | 723 |
| 30 Sep 17 | 7,182 | 1,478 | 1,191 | 695 |
| 30 Jun 17 | 6,947 | 1,337 | 1,182 | 667 |
| 31 Mar 17 | 6,802 | 1,333 | 1,118 | 642 |
| 31 Dec 16 | 6,656 | 1,329 | 1,055 | 617 |
| 30 Sep 16 | 6,386 | 1,286 | 1,033 | 615 |
| 30 Jun 16 | 6,115 | 1,242 | 1,011 | 614 |
| 31 Mar 16 | 5,983 | 1,324 | 954 | 564 |
| 31 Dec 15 | 5,850 | 1,406 | 897 | 513 |
| 30 Sep 15 | 5,654 | 1,392 | 841 | 488 |
Des revenus de qualité: CSL a un important ponctuel perte de $2.1B impactant ses 12 derniers mois de résultats financiers à 31st December, 2025.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de CSL sont inférieures à celles de l'année dernière CSL. (9.1%) sont inférieures à celles de l'année dernière (18%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de CSL ont augmenté de 0.3% par an au cours des 5 dernières années.
Accélération de la croissance: CSL a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: CSL a enregistré une croissance négative de ses bénéfices ( -49.2% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Biotechs ( 6.8% ).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de CSL ( 6.7% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/11 19:15 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CSL Limited est couverte par 27 analystes. 16 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Lyanne Harrison | BofA Global Research |